Roche Holding AG

Conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, financial planning, and innovative technologies. Focuses on networking, case studies, presentations, and round tables.

FDA approves Jazz Pharmaceuticals' Ziihera (zanidatamab), the first dual HER2-targeted bispecific antibody for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, administered every two weeks.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, real-world data, and risk-based monitoring, among others. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study opportunities.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, data integration, outsourcing, and risk-based monitoring. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study presentations.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.

Biotechnology Market to grow at 13.9% CAGR from 2024-2031, driven by health, agriculture, and industrial applications. Valued at USD 1.21 Trillion in 2022, it is expected to reach USD 3.90 Trillion by 2031.

Halozyme offers €2 billion cash for Evotec, aiming to create a $2 billion revenue company by 2025 with complementary platforms and growth potential.

The atopic dermatitis market is projected to grow from $7.51 billion in 2023 to $15.27 billion by 2028, driven by advancements in biologic therapies, personalized medicine, and product innovations. Key players include Sanofi SA, Regeneron Pharmaceuticals Inc., and Novartis International AG.

The biotechnology reagents market is projected to grow from $78.82 billion in 2023 to $124.95 billion by 2028, driven by advancements in biotechnology research, single-cell analysis, and synthetic biology. Key drivers include the rise in chronic disease prevalence and technological innovations like the PhysioMimix reagent kit. Major players in the market include Life Technologies Corporation, Abbott Laboratories, and Thermo Fisher Scientific Inc.